Discovery of TRAF-2 and NCK-interacting kinase (TNIK) inhibitors by ligand-based virtual screening methodsElectronic supplementary information (ESI) available. See DOI: 10.1039/c5md00090d

TRAF-2 and NCK-interacting kinase (TNIK) is a serine-threonine kinase with a proposed role in Wnt/β-catenin and JNK pathways. Due to its implication in Wnt-mediated colorectal carcinogenesis, selective TNIK inhibition has emerged as an attractive anti-cancer therapeutic strategy. So far, only a few TNIK inhibitors have been described and none of them reached advanced preclinical development. In this study, a virtual screening approach was applied for the investigation of novel TNIK inhibitors. The best performing ShaEP methodology for similarity searching was applied for screening of a commercially available small-molecule database. Among several discovered TNIK kinase inhibitors, a compound containing the furan-2-carboxamide scaffold was found to be the most active, with IC 50 = 0.85 μM. An advanced substructure search led to the discovery of a more potent and selective compound with IC 50 = 258 nM. The most active compounds were tested in vitro for their effect on the Wnt/β-catenin pathway and proliferation of Wnt-active colorectal cancer cells. The compounds identified in this study represent attractive starting points for the development of more potent and selective small-molecule TNIK inhibitors for both therapeutic application and research into TNIK's biological role. TRAF-2 and NCK-interacting kinase (TNIK) is a serine-threonine kinase with a proposed role in Wnt/β-catenin and JNK pathways.